• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Tau to Present at Jefferies Global Healthcare Conference

    5/28/25 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email

    JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025.

    Event:Jefferies Global Healthcare Conference
    Format:Presentation
    Date:June 5, 2025
    Time:1:25 – 1:55PM ET
    Location:New York, NY
      

    Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule.

    About Alpha Tau Medical Ltd.

    Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

    About Alpha DaRT®

    Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

    Investor Relations Contact:

    [email protected]



    Primary Logo

    Get the next $DRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Alpha Tau with a new price target

      Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

      12/15/23 8:07:49 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on Alpha Tau with a new price target

      H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

      4/24/23 7:44:43 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Alpha Tau with a new price target

      Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00

      4/14/22 7:17:36 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    SEC Filings

    See more
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      5/28/25 8:32:30 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      5/19/25 4:02:08 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      5/13/25 4:05:02 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Tau to Present at Jefferies Global Healthcare Conference

      JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025. Event:Jefferies Global Healthcare ConferenceFormat:PresentationDate:June 5, 2025Time:1:25 – 1:55PM ETLocation:New York, NY   Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd.Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and

      5/28/25 8:30:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

      - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -       - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma (HNSCC) - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-l

      5/19/25 4:01:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

      JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

      5/12/25 4:01:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

      JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

      5/12/25 4:01:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

      - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

      3/12/25 4:02:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

      JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

      12/17/24 9:00:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care